Revance Therapeutics reported $-57842000 in EBIT for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebit Change
Aerie Pharmaceuticals AERI:US $ -18137000 15.51M
ALKERMES ALKS:US -34457000 7.87M
Bristol Myers Squibb BMY:US $ 3197M 9M
Cara Therapeutics CARA:US $ -4472000 23.44M
Eli Lilly And LLY:US $ 1650.5M 919.4M
Horizon Pharma HZNP:US 147M 49.44M
JAZZ PHA JAZZ:US 126.35M 38.8M
Johnson & Johnson JNJ:US $ 6941M 599M
Merk MRK:US $ 5711M 652M
Neurocrine Biosciences NBIX:US $ 54.7M 51.6M
Pacira Pharmaceuticals PCRX:US $ 13.18M 8.55M
Revance Therapeutics RVNC:US $ -57842000 4.38M
Supernus Pharmaceuticals SUPN:US $ 11.35M 9.38M
Teva Pharmaceutical Industries TEVA:US 734M 55M